Autopsy report · NCT02447939

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

“Change in strategy”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Conditions

Melanoma

Interventions

Dabrafenib; Trametinib

Participants

0

Trials that died the same way

• Choroidal Changes Post Short Term Exposure To Virtual Reality Devices
  “Strategy change” (96% match in meaning)
• Automated Breast Ultrasound Case Collection Registry
  “Change in business strategy” (83% match in meaning)
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (82% match in meaning)
• Evaluation of Safety and Efficacy of Dehydrated Human Amnion-Intermediate-Chorion Membrane (dHAICM) Allograft in Treatment of Partial Thickness Thermal Burns
  “Change in company strategy.” (77% match in meaning)
• Efficacy and Safety of Tiradentes Association in the Treatment of Acute Pain
  “Strategy review” (70% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.